# Axsome (AXSM) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/AXSM
## Company Profile
- Ticker: AXSM
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: CNS
## Stock Data
- Close: 215.77 USD
- Market cap: 11432301614.56 USD
- Last updated: 2026-08-11
## Business Overview
### CNS Commercial Portfolio
Axsome Therapeutics develops and commercializes medicines for central nervous system disorders. Its business combines marketed products in depression, migraine and sleep disorders with a pipeline spanning psychiatry and neurology.
### AUVELITY
AUVELITY is an oral NMDA receptor antagonist and sigma-1 receptor agonist approved for major depressive disorder and agitation associated with dementia due to Alzheimer’s disease. The Alzheimer’s agitation indication expands the product into a second large neuropsychiatric market.
### Migraine and Sleep Medicine
SYMBRAVO is an acute migraine treatment, while SUNOSI is approved for excessive daytime sleepiness associated with obstructive sleep apnea or narcolepsy. Together they diversify Axsome’s commercial base beyond AUVELITY.
### AXS-12 and Solriamfetol Development
AXS-12 has been submitted to the FDA for cataplexy in narcolepsy. Solriamfetol is also being developed in pediatric Phase 3 trials for attention-deficit hyperactivity disorder and in the ENGAGE and SUSTAIN programs.
### Earlier CNS Pipeline
AXS-05 is planned for pivotal study in smoking cessation. AXS-20, or balipodect, is a Phase 3-ready PDE10A inhibitor being prepared for development in schizophrenia and Tourette syndrome.
## Why The Stock Is Moving

Following the latest company update, “Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update”, AXSM closed up 3.83% at $220.89 on Aug 10, 2026. The move occurred in the trading session associated with this earnings update.

## Future Catalysts

- Initiation of the pivotal Phase 2/3 AXS-05 smoking-cessation trial in the third quarter of 2026.
- Topline results from the Phase 3 ENGAGE study of solriamfetol in binge-eating disorder in the fourth quarter of 2026.
- Topline results from the Phase 3 SUSTAIN study of solriamfetol in shift-work disorder in 2027.
- FDA action on the AXS-12 NDA for cataplexy in narcolepsy by the May 1, 2027 PDUFA date.

## Recent News
- 2026-08-10 11:00 EST — [Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/AXSM/axsome-therapeutics-reports-second-quarter-2026-financial-results-and-provides-b-55c7b01c) — Source: Axsome
- 2026-07-15 11:00 EST — [Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy](https://biopharmsignal.com/news/AXSM/axsome-therapeutics-announces-fda-acceptance-of-new-drug-application-for-axs-12--867574ca) — Source: Axsome
- 2026-07-14 11:00 EST — [Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10](https://biopharmsignal.com/news/AXSM/axsome-therapeutics-to-report-second-quarter-2026-financial-results-on-august-10-d05e9c7e) — Source: Axsome
- 2026-07-07 11:00 EST — [Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)](https://biopharmsignal.com/news/AXSM/axsome-therapeutics-initiates-focus-2-phase-3-trial-of-solriamfetol-in-children--f3b8fe5b) — Source: Axsome
- 2026-06-26 11:00 EST — [Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)](https://biopharmsignal.com/news/AXSM/axsome-therapeutics-initiates-focus-3-phase-3-trial-of-solriamfetol-in-adolescen-328278bb) — Source: Axsome